knowledge -WSS

knowledge

author：explore 2025-09-27 22:47:44 - browse：19

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

hotspot

entertainment

WSS

Fentanyl is making it harder to start addiction treatment

For Medicare Advantage, Democrats want stronger protections around AI

H5N1 bird flu outbreak: Second human case reported, in Michigan

Private equity deals in Medicare Advantage declines

Medicare threatens to cut off funding for HCA's Mission hospital

What should King Charles tell the public about his cancer?

hotspot

knowledge

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

What we’ve learned from the Aduhelm mess

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Questions and answers about ramping up H5N1 bird flu vaccine

The cancer drug shortage isn’t new — and neither are the solutions

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Medicare proposal to cover medical devices draws a mixed reaction

What should King Charles tell the public about his cancer?

Walensky prepares to leave CDC — and Congress — behind

UnitedHealth argues against case alleging wrongful AI care denials

leisure time

Bird flu surveillance in wastewater gets boost from consortium

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Vaccine advisory panel ACIP left half staffed by HHS

H5N1 bird flu outbreak: Second human case reported, in Michigan

The Readout: Gilead, Bernie Sanders, and other pharma news

Eyeing GLP

knowledge

hotspot

entertainment

hotspot